$SNPX
Synaptogenix, Inc.

2024 Q4 Form 10-Q Financial Statement

#000141057824001891 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.137M
YoY Change -6.82%
% of Gross Profit
Research & Development $222.9K
YoY Change 5.09%
% of Gross Profit
Depreciation & Amortization $1.690K
YoY Change -83.1%
% of Gross Profit
Operating Expenses $1.360M
YoY Change -4.9%
Operating Profit
YoY Change
Interest Expense $266.7K
YoY Change -82.46%
% of Operating Profit
Other Income/Expense, Net -$4.382M
YoY Change -299.83%
Pretax Income -$5.742M
YoY Change -852.36%
Income Tax
% Of Pretax Income
Net Earnings -$5.742M
YoY Change -852.36%
Net Earnings / Revenue
Basic Earnings Per Share $4.58
Diluted Earnings Per Share $4.58
COMMON SHARES
Basic Shares Outstanding 1.356M 1.314M
Diluted Shares Outstanding 1.320M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.04M
YoY Change -30.53%
Cash & Equivalents $19.60M
Short-Term Investments $2.443M
Other Short-Term Assets $2.655M
YoY Change 335.17%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.28M
YoY Change -31.11%
LONG-TERM ASSETS
Property, Plant & Equipment $14.10K
YoY Change -28.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $531.9K
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $546.0K
YoY Change 2669.6%
TOTAL ASSETS
Total Short-Term Assets $22.28M
Total Long-Term Assets $546.0K
Total Assets $22.83M
YoY Change -29.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $286.4K
YoY Change 33.67%
Accrued Expenses $54.54K
YoY Change -28.74%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $340.9K
YoY Change -81.25%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $9.369M
YoY Change 344.03%
Total Long-Term Liabilities $9.369M
YoY Change 344.03%
TOTAL LIABILITIES
Total Short-Term Liabilities $340.9K
Total Long-Term Liabilities $9.369M
Total Liabilities $9.710M
YoY Change 146.96%
SHAREHOLDERS EQUITY
Retained Earnings -$41.51M
YoY Change 28.2%
Common Stock $137.00
YoY Change -92.18%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $12.80M
YoY Change
Total Liabilities & Shareholders Equity $22.83M
YoY Change -29.46%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$5.742M
YoY Change -852.36%
Depreciation, Depletion And Amortization $1.690K
YoY Change -83.1%
Cash From Operating Activities -$1.031M
YoY Change -11.88%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.320M
YoY Change
NET CHANGE
Cash From Operating Activities -1.031M
Cash From Investing Activities 0.000
Cash From Financing Activities -4.320M
Net Change In Cash -5.351M
YoY Change 357.32%
FREE CASH FLOW
Cash From Operating Activities -$1.031M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001571934
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1320000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
428200
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1192500
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
339100
dei Entity Registrant Name
EntityRegistrantName
Synaptogenix, Inc.
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.58
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.84
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
6.63
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
37.01
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
CY2024Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.04
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40458
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1585656
dei Entity Address Address Line1
EntityAddressAddressLine1
1185 Avenue of the Americas
dei Entity Address Address Line2
EntityAddressAddressLine2
3rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
973
dei Local Phone Number
LocalPhoneNumber
242-0005
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
SNPX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1355613
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19625780
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28661498
CY2023Q4 snpx Prepaid Clinical Trial Expenses
PrepaidClinicalTrialExpenses
375085
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2443300
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1438500
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
211230
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
57677
CY2024Q3 us-gaap Assets Current
AssetsCurrent
22280310
CY2023Q4 us-gaap Assets Current
AssetsCurrent
30532760
CY2024Q3 us-gaap Equity Method Investments
EquityMethodInvestments
531927
CY2023Q4 us-gaap Equity Method Investments
EquityMethodInvestments
562402
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14100
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
18505
CY2024Q3 us-gaap Assets
Assets
22826337
CY2023Q4 us-gaap Assets
Assets
31113667
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
286350
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
444633
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
54542
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
435891
CY2023Q4 snpx Temporary Equity Accrued Amount Payable Current
TemporaryEquityAccruedAmountPayableCurrent
3395945
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
340892
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4276469
CY2024Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
3251000
CY2023Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
140000
CY2024Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
6118000
CY2023Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1113000
CY2024Q3 us-gaap Liabilities
Liabilities
9709892
CY2023Q4 us-gaap Liabilities
Liabilities
5529469
CY2024Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2023Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
6000
CY2024Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2024Q3 snpx Temporary Equity Liquidation Preference Percentage Of Accrued Dividends
TemporaryEquityLiquidationPreferencePercentageOfAccruedDividends
0.07
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1355613
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1355613
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
963489
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
963489
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
137
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
96
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
54309822
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
57957008
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
5702
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
902
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41513689
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-33610748
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12801972
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
24347258
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22826337
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
31113667
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
222897
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
212103
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1174214
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1397031
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1136772
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1217689
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3457916
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4784415
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
1359669
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
1429792
us-gaap Operating Expenses
OperatingExpenses
4632130
us-gaap Operating Expenses
OperatingExpenses
6181446
CY2024Q3 us-gaap Interest Income Other
InterestIncomeOther
300681
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
549995
us-gaap Interest Income Other
InterestIncomeOther
1094584
us-gaap Interest Income Other
InterestIncomeOther
1373511
CY2024Q3 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-12025
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-30475
CY2024Q3 snpx Warrant Issuance Cost
WarrantIssuanceCost
618375
snpx Warrant Issuance Cost
WarrantIssuanceCost
618375
CY2024Q3 snpx Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
3812625
snpx Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
3812625
CY2024Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
218000
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-674000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
314000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1055000
CY2024Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-22000
CY2023Q3 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
969000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1091000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1289600
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4382344
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2192995
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2589891
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1138911
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5742013
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
763203
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7222021
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5042535
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5742013
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
763203
us-gaap Net Income Loss
NetIncomeLoss
-7222021
us-gaap Net Income Loss
NetIncomeLoss
-5042535
CY2024Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
306725
CY2023Q3 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1124628
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
680919
us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
1814277
snpx Deemed Dividend Related To Temporary Equity Extinguishment
DeemedDividendRelatedToTemporaryEquityExtinguishment
5693000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6048738
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-361425
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7902940
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12549812
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
5400
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4800
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6043338
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-361425
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7898140
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12549812
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.58
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.84
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
37.01
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1320000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
428200
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1192500
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
339100
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
24830127
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15064
CY2023Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4500
CY2023Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
192500
CY2023Q3 snpx Deemed Dividend Extinguishment Of Preferred Stock
DeemedDividendExtinguishmentOfPreferredStock
-116757
CY2023Q3 snpx Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
-3892879
CY2023Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
2455656
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
763203
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
26740860
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
18796602
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3791
CY2024Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
4500
CY2024Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
287334
CY2024Q3 snpx Adjustment To Additional Paid In Capital Temporary Equity Extinguishment Of Deemed Dividend
AdjustmentToAdditionalPaidInCapitalTemporaryEquityExtinguishmentOfDeemedDividend
-19392
CY2024Q3 snpx Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
-341697
CY2024Q3 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
301279
CY2024Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
5400
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5742013
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12801972
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32692973
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
994261
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
113500
us-gaap Dividends Preferred Stock
DividendsPreferredStock
882149
snpx Adjustment To Additional Paid In Capital Temporary Equity Extinguishment Of Deemed Dividend
AdjustmentToAdditionalPaidInCapitalTemporaryEquityExtinguishmentOfDeemedDividend
-116757
snpx Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
-3892879
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
4911312
us-gaap Net Income Loss
NetIncomeLoss
-5042535
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
26740860
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
24347258
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21618
us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
113501
us-gaap Dividends Preferred Stock
DividendsPreferredStock
409834
snpx Adjustment To Additional Paid In Capital Temporary Equity Extinguishment Of Deemed Dividend
AdjustmentToAdditionalPaidInCapitalTemporaryEquityExtinguishmentOfDeemedDividend
-271086
snpx Temporary Equity Redemption Value
TemporaryEquityRedemptionValue
-1430327
us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
5212591
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4800
us-gaap Net Income Loss
NetIncomeLoss
-7222021
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
12801972
us-gaap Net Income Loss
NetIncomeLoss
-7222021
us-gaap Net Income Loss
NetIncomeLoss
-5042535
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
21618
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
994261
snpx Warrant Issuance Cost
WarrantIssuanceCost
618375
snpx Loss On Issuance Of Preferred Stock
LossOnIssuanceOfPreferredStock
3812625
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
314000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1055000
snpx Fair Value Of Derivative Liability
FairValueOfDerivativeLiability
1091000
snpx Fair Value Of Derivative Liability
FairValueOfDerivativeLiability
-1289600
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-30475
snpx Issuance Of Stock And Warrants For Services
IssuanceOfStockAndWarrantsForServices
113501
snpx Issuance Of Stock And Warrants For Services
IssuanceOfStockAndWarrantsForServices
113500
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4405
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5137
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-221531
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-493987
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-158283
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-445988
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-381349
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-460171
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
3505898
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
935326
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3716123
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4107209
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
1000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2707
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2707
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
4463000
snpx Payments To Redemption Of Temporary Equity
PaymentsToRedemptionOfTemporaryEquity
7831677
snpx Payments To Redemption Of Temporary Equity
PaymentsToRedemptionOfTemporaryEquity
1000000
snpx Payments To Dividends Of Temporary Equity
PaymentsToDividendsOfTemporaryEquity
950918
snpx Payments To Dividends Of Temporary Equity
PaymentsToDividendsOfTemporaryEquity
641015
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-4319595
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1641015
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-9035718
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-5750931
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
28661498
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37478480
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19625780
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31727549
us-gaap Stock Issued1
StockIssued1
1430327
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
4800
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Note 1 – Organization, Business, Risks and Uncertainties:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;">Organization and Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On May 17, 2020, Neurotrope, Inc. (“Neurotrope” or “the Parent”) announced plans for the complete legal and structural separation of its wholly owned subsidiary, Neurotrope Bioscience, Inc., from Neurotrope (the “Spin-Off”). Under the Separation and Distribution Agreement, Neurotrope planned to distribute all of its equity interest in this wholly owned subsidiary to Neurotrope’s stockholders. Following the Spin-Off, Neurotrope does not own any equity interest in the Company, and the Company operates independently from Neurotrope. On December 7, 2020, the Company became an independent company, Synaptogenix, Inc., a Delaware corporation (formerly known as Neurotrope Bioscience, Inc.) (the “Company” or “Synaptogenix”) when the Company filed an amended and restated certificate of incorporation which, among other things, changed its name to Synaptogenix, Inc. The Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), are listed on The Nasdaq Capital Market under the symbol “SNPX.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On April 24, 2023, the Company received a written notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days, the Common Stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company received an initial grace period of 180 calendar days, or until October 23, 2023 (the “Initial Compliance Period”), to regain compliance with the Minimum Bid Price Requirement. On October 24, 2023, the Company received a second written notice from Nasdaq, notifying the Company that it had not regained compliance with the Minimum Bid Price Requirement during the Initial Compliance Period and granting the Company an additional grace period of 180 calendar days, or until April 22, 2024, to regain compliance. On April 4, 2024, the Company effected a <span style="-sec-ix-hidden:Hidden_OCpvSVknik6vKX3j276A_A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> - for - twenty - five reverse stock split of the Common Stock (the “Reverse Stock Split”) in order to regain compliance with the Minimum Bid Price Requirement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On April 22, 2024, Nasdaq informed the Company that it had regained compliance with the Minimum Bid Price Requirement and that the matter was closed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On April 4, 2024, the Company effected the Reverse Stock Split. All share and per share information in this quarterly report have been retroactively adjusted to reflect the Reverse Stock Split.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;">Liquidity Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">As of September 30, 2024, the Company had approximately $19.6 million in cash and cash equivalents as compared to $28.7 million at December 31, 2023. The Company expects that its current cash and cash equivalents, approximately $18.3 million as of the date of this Quarterly Report on Form 10-Q, will be sufficient to support its projected operating requirements and financial commitments for at least the next 12 months from the date of this Quarterly Report. The operating requirements include the current development plans for Bryostatin-1, the Company’s novel drug candidate targeting the activation of Protein Kinase C Epsilon and other development projects. The financial commitments include the potential redemption of the Series C Convertible Preferred Stock for cash.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company expects to need additional capital in order to initiate and pursue potential additional development projects, including the continuing development beyond the ongoing Phase 2 trial of Bryostatin-1. Any additional equity financing, if available, may not be on favorable terms and would likely be significantly dilutive to the Company’s current stockholders, and debt financing, if available, may involve restrictive covenants. If the Company is able to access funds through collaborative or licensing arrangements, it may be required to relinquish rights to some of its technologies or product candidates that the Company would otherwise seek to develop or commercialize on its own, on terms that are not favorable to the Company. The Company’s ability to access capital when needed is not assured and, if not achieved on a timely basis, will likely have a materially adverse effect on its business, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Other Risks and Uncertainties</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company operates in an industry that is subject to rapid technological change, intense competition, and significant government regulation. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological and regulatory. Such factors include, but are not necessarily limited to, the results of clinical testing and trial activities, the ability to obtain regulatory approval, the limited supply of raw materials, the ability to obtain favorable licensing, manufacturing or other agreements, including risk associated with the Company’s Cognitive Research Enterprises, Inc. (formerly known as the Blanchette Rockefeller Neurosciences Institute, or BRNI) (“CRE”) licensing agreement, and the ability to raise capital to achieve strategic objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">CRE has entered into a material transfer agreement with the National Cancer Institute of the National Institutes of Health (“NCI”), pursuant to which the NCI has agreed to supply bryostatin required for the Company’s pre-clinical research and clinical trials. This agreement does not provide for a sufficient amount of bryostatin to support the completion of all of the clinical trials that the Company is required to conduct in order to seek U.S. Food and Drug Administration (“FDA”) approval. Therefore, CRE or the Company would have to enter into one or more subsequent agreements with the NCI for the supply of additional amounts of bryostatin. If CRE or the Company were unable to secure such additional agreements, or if the NCI otherwise discontinues the supply, the Company would have to either secure another source of bryostatin or discontinue its efforts to develop and commercialize Bryostatin-1 for the treatment of AD. In June 2020, the Company entered into a supply agreement (the “Supply Agreement”) with BryoLogyx Inc. (“BryoLogyx”), pursuant to which BryoLogyx agreed to be the Company’s exclusive supplier of synthetic bryostatin. Pursuant to the terms of the Supply Agreement, the Company received its initial order of one gram of synthetic bryostatin. See Note 3.</p>
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 snpx Number Of Preceding Consecutive Business Days Failure To Maintain Minimum Closing Bid Price
NumberOfPrecedingConsecutiveBusinessDaysFailureToMaintainMinimumClosingBidPrice
30
CY2023Q2 snpx Minimum Closing Bid Price Failed To Maintain In Preceding Thirty Consecutive Business Days
MinimumClosingBidPriceFailedToMaintainInPrecedingThirtyConsecutiveBusinessDays
1.00
CY2023Q2 snpx Number Of Calendar Days Of Grace Period To Attain Minimum Closing Bid Price
NumberOfCalendarDaysOfGracePeriodToAttainMinimumClosingBidPrice
180
CY2023Q4 snpx Number Of Calendar Days Of Grace Period To Attain Minimum Closing Bid Price
NumberOfCalendarDaysOfGracePeriodToAttainMinimumClosingBidPrice
180
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19600000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
28700000
CY2024Q3 snpx Cash And Cash Equivalents Expected Amount At Financial Reporting Date
CashAndCashEquivalentsExpectedAmountAtFinancialReportingDate
18300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make significant estimates that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Management evaluates its estimates on an ongoing basis using historical experience and other factors, including the general economic environment and actions it may take in the future. The Company adjusts such estimates when facts and circumstances dictate. However, these estimates may involve significant uncertainties and judgments and cannot be determined with precision. In addition, these estimates are based on management’s best judgment at a point in time and as such these estimates may ultimately differ from actual results.</p>
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1719830
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
371204
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1669660
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
370180
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
900000
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
18700000
CY2024Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
52000
CY2024Q3 snpx Capitalized Research And Development Services
CapitalizedResearchAndDevelopmentServices
0
CY2023Q4 snpx Capitalized Research And Development Services
CapitalizedResearchAndDevelopmentServices
0
CY2024Q3 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
98200000
CY2024Q3 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
31500000
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
snpx Number Of Votes Per Share Owned
NumberOfVotesPerShareOwned
1
CY2024Q3 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
0
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
3395945
CY2024Q3 snpx Percentage Of Common Stock Shares Agreed To Register Under Series C Registration Rights Agreements
PercentageOfCommonStockSharesAgreedToRegisterUnderSeriesCRegistrationRightsAgreements
2
CY2024Q3 snpx Percentage Of Warrants Agreed To Register Under Series C Registration Right Agreement
PercentageOfWarrantsAgreedToRegisterUnderSeriesCRegistrationRightAgreement
2
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
29674
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
153.75
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y10M24D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3200
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.39
snpx Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P8Y11M23D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
32874
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
139.27
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y7D
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
29674
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
153.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y11M12D
CY2024Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2024Q3 us-gaap Share Price
SharePrice
3.02
CY2023Q4 us-gaap Share Price
SharePrice
6.80
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7828
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y6M7D
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3791
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15064
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21618
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
994261
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3791
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15064
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
21618
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
994261
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
287436
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
1331431
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
0
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
1618867
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
46.51
snpx Warrants And Rights Outstanding Remaining Term
WarrantsAndRightsOutstandingRemainingTerm
P4Y4M9D
CY2024Q3 snpx Intrinsic Value Of Warrants
IntrinsicValueOfWarrants
34000
CY2024Q3 us-gaap Share Price
SharePrice
3.02
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 snpx Non Rule10b51 Arr Modified Flag
NonRule10b51ArrModifiedFlag
false
CY2024Q3 snpx Rule10b51 Arr Modified Flag
Rule10b51ArrModifiedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0001410578-24-001891-index-headers.html Edgar Link pending
0001410578-24-001891-index.html Edgar Link pending
0001410578-24-001891.txt Edgar Link pending
0001410578-24-001891-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snpx-20240930.xsd Edgar Link pending
snpx-20240930x10q.htm Edgar Link pending
snpx-20240930xex31d1.htm Edgar Link pending
snpx-20240930xex31d2.htm Edgar Link pending
snpx-20240930xex32d1.htm Edgar Link pending
snpx-20240930xex32d2.htm Edgar Link pending
snpx-20240930_def.xml Edgar Link unprocessable
snpx-20240930_lab.xml Edgar Link unprocessable
snpx-20240930_pre.xml Edgar Link unprocessable
snpx-20240930x10q_htm.xml Edgar Link completed
snpx-20240930_cal.xml Edgar Link unprocessable